<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999556</url>
  </required_header>
  <id_info>
    <org_study_id>LCI-HEM-SPEC-001</org_study_id>
    <secondary_id>00008179</secondary_id>
    <nct_id>NCT01999556</nct_id>
  </id_info>
  <brief_title>LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia</brief_title>
  <official_title>LCI-HEM-SPEC-001: Tissue Collection for Familial Acute Myelogenous Leukemia Genetic Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawrence Druhan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain high quality specimens for molecular studies for the&#xD;
      identification and characterization of genetic mutations involved in the pathogenesis of&#xD;
      familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic&#xD;
      clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for&#xD;
      molecular analyses. Some specimens sent to Washington University may also be used for quality&#xD;
      control analyses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a specimen collection study for patients receiving standard of care treatment for&#xD;
      AML. Specimens collected will be 1) bone marrow biopsy and aspiration, 2) peripheral blood,&#xD;
      3) skin punch biopsy, and 4) oral rinse. Collection of these specimens will be at timepoints&#xD;
      determined by the patient's standard of care and their physician Investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 22, 2016</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with the mutation for acute myelogenous leukemia.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia, Myelogenous, Acute</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <description>Specimen Collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relative</arm_group_label>
    <description>Specimen Collection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients must have a diagnosis of acute myelogenous leukemia. Family members of patients&#xD;
        with acute myelogenous leukemia may be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must have a diagnosis of acute myelogenous leukemia.&#xD;
&#xD;
          -  Family members of patients with acute myelogenous leukemia may be enrolled.&#xD;
&#xD;
          -  Informed consent must be provided by the patient or his/her legal guardian in accord&#xD;
             with the practices of Levine Cancer Institute and Atrium Health.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Known infection with Hepatitis B or C, HTLV, or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Druhan, PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Lawrence Druhan</investigator_full_name>
    <investigator_title>Research Group Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

